Yellow fever vaccine - Najit Technologies
Alternative Names: HydroVax-002 YFV; Inactivated YFV vaccineLatest Information Update: 28 Feb 2025
At a glance
- Originator Najit Technologies
- Developer Najit Technologies; National Institute of Allergy and Infectious Diseases
- Class Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Yellow fever
Most Recent Events
- 28 Feb 2025 No recent reports of development identified for phase-I development in Yellow-fever(Prevention, In adults) in USA (IM)
- 24 Apr 2023 Najit Technologies and National Institute of Allergy and Infectious Diseases (NIAID) complete a phase I trial in Yellow fever (Prevention, In adults) in USA (IM) (NCT05172544)
- 13 Jan 2022 Phase-I clinical trials in Yellow fever (Prevention, In adults) in USA (IM) (NCT05172544)